XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.2
FINANCIAL INSTRUMENTS - Fair Value of Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
Jul. 10, 2020
Mar. 13, 2017
Jun. 30, 2020
Mar. 07, 2017
Fair Value Measurements        
Closing sale price (in dollars per share)     $ 52.47  
Myoscience Acquisition        
Fair Value Measurements        
Acquisition-related contingent consideration     $ 20,800  
Convertible Senior Notes Due 2022        
Fair Value Measurements        
Closing sale price (in dollars per share)       $ 48.65
Initial conversion price of notes into common stock (in dollars per share)   $ 66.89    
Convertible Senior Notes Due 2022 | Maximum        
Fair Value Measurements        
Debt instrument, convertible, conversion premium (in shares)   5.2    
Convertible Senior Notes Due 2022 | Maximum | Subsequent Event        
Fair Value Measurements        
Debt instrument, convertible, conversion premium (in shares) 2.4      
Level 1        
Fair Value Measurements        
Equity Investments     10,032  
Level 1 | Myoscience Acquisition        
Fair Value Measurements        
Acquisition-related contingent consideration     0  
Level 1 | Convertible Senior Notes Due 2022        
Fair Value Measurements        
Convertible senior notes     0  
Level 2        
Fair Value Measurements        
Equity Investments     0  
Level 2 | Myoscience Acquisition        
Fair Value Measurements        
Acquisition-related contingent consideration     0  
Level 2 | Convertible Senior Notes Due 2022        
Fair Value Measurements        
Convertible senior notes     378,206  
Level 3        
Fair Value Measurements        
Equity Investments     0  
Level 3 | Myoscience Acquisition        
Fair Value Measurements        
Acquisition-related contingent consideration     20,830  
Level 3 | Convertible Senior Notes Due 2022        
Fair Value Measurements        
Convertible senior notes     0  
Reported Value Measurement        
Fair Value Measurements        
Equity Investments     10,032  
Reported Value Measurement | Myoscience Acquisition        
Fair Value Measurements        
Acquisition-related contingent consideration     20,830  
Reported Value Measurement | Convertible Senior Notes Due 2022        
Fair Value Measurements        
Convertible senior notes     $ 314,182  
Unsecured Debt | Convertible Senior Notes Due 2022        
Fair Value Measurements        
Stated interest rate (as a percent)   2.375% 2.375%